Abstract
In this chapter we review the development of melanin concentrating hormone receptor 1 (MCH-R1) antagonists as a new perspective for the pharmacological treatment of obesity. We will initially focus on melanin concentrating hormone (MCH): structure, localization and function in the regulation of feeding behavior and energy balance and two receptors for MCH in humans. We will then review the discovery of the first MCH-R1 antagonists, the drug-design strategies used to obtained new series of MCH-R1 antagonists and an analysis of their structure-activity relationship. Finally, we will evaluate the absorption, distribution, metabolism and excretion, efficacy, safety and toxicity in preclinical and clinical trials.
Keywords: Development, Melanin concentrating hormone (MCH), Melanin concentrating hormone receptor 1 (MCH-R1), Structure-activity relationship (SAR), Obesity.
Related Journals
Drug Delivery Letters
Recent Advances in Anti-Infective Drug Discovery
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Bioactive Compounds
Current Drug Delivery
Current Drug Safety
Drug Metabolism and Bioanalysis Letters
Recent Advances in Drug Delivery and Formulation
Reviews on Recent Clinical Trials
Current Drug Metabolism
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
